MEGALOBOX 2: NOMAD to Premiere in April 2021 on TOKYO MX & BS11
1.2.2021 10:30:00 EET | Business Wire | Press release
TMS Entertainment today announced that MEGALOBOX 2: NOMAD , the highly anticipated sequel to the internationally acclaimed anime series MEGALOBOX , will premiere in April 2021 on Japanese television networks TOKYO MX and BS11.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210131005078/en/
teaser visual of Nomad (Graphic: Business Wire)
MEGALOBOX , a series based on Tomorrow’s Joe by Asao Takamori (Ikki Kajiwara) and Tetsuya Chiba, was originally released in 2018 to commemorate the 50th anniversary of the original manga title.
Teaser Trailer and Visuals Revealed
The teaser trailer and visuals have also been revealed ahead of the broadcast.
Watch the teaser now: https://youtu.be/bjl0qMgrugQ
The striking teaser visual, drawn by the director Yo Moriyama, shows Joe standing with his gear covering the body full of scars. Seven years after Joe’s reign as the first Megalonia champion, we now find him calling himself Nomad. The accompanying teaser trailer reveals a glimpse of what had happened to Joe after the fateful match with Yuri in MEGALOBOX.
ABOUT MEGALOBOX 2: NOMAD
In the end, “Gearless” Joe was the one that reigned as the champion of Megalonia, a first ever megalobox tournament. Fans everywhere were mesmerized by the meteoric rise of Joe who sprung out from the deepest underground ring to the top in mere three months and without the use of gear. Seven years later, “Gearless” Joe was once again fighting in underground matches. Adorned with scars and once again donning his gear, but now known only as Nomad…
WEB: https://megalobox.com/
Twitter: https://twitter.com/joe50_megalobox
STAFF
Original Concept: Tomorrow’s Joe
Original Comic Books Created by Asao Takamori, Tetsuya Chiba / Published by Kodansha.
Director / Concept Designer: Yo Moriyama
Scenario: Katsuhiko Manabe, Kensaku Kojima
Character Designer: Ayumi Kurashima
Sub Character Designer: Naomi Kaneda
Music: mabanua
Animation production: TMS Entertainment Co., Ltd.
Produced by MEGALOBOX2 Project
CAST
Joe / NOMAD: Yoshimasa Hosoya
GANSAKU NANBU: Shiro Saito
YURI: Hiroki Yasumoto
SACHIO: Michiyo Murase
© Asao Takamori, Tetsuya Chiba/Kodansha/MEGALOBOX2 project. All Rights Reserved.
About TMS Entertainment
By maintaining a balance of creativity and business production, TMS Entertainment provides a one-stop shop for services from IP creation to consumer satisfaction improvement, centered around its animation production, licensing, and content businesses. TMS Entertainment has continuously produced much-loved anime titles in Japan, including "Lupin the 3rd," "Dr. STONE," and “MEGALOBOX” while connecting its library of over 12,000 episodes across a total of 420 titles to its global business.
WEB: https://www.tms-e.co.jp/global/
Twitter:
https://twitter.com/tmsanime
Facebook:
https://www.facebook.com/AnimeTMS
Instagram:
https://www.instagram.com/tmsanime/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210131005078/en/
Contact information
TMS Entertainment Co., Ltd. Paris Office
International Sales & Licensing
Cinzia Mariani
E-mail: tmsparis@tms-e.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 16:07:00 EEST | Press release
Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™, and API Media operations into a new stand-alone public company, which is proposed to be named “API Media”. The Company has reserved the ticker symbol “ADIO” for the proposed spin-out entity and currently intends that API Media will be listed on NASDAQ following completion of the proposed transactions, which remain subject to approval by the Company’s board of directors, definitive agreement, and satisfaction of closing conditions, as well as any regulatory approvals that may be required in connection therewith. The Company has engaged Houlihan Lokey as its financial advisor and Paul Hastings LLP as its lega
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura ® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 15:50:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs). These data were presented (Abstract ID: P0851) today at the 2026 European Academy of Dermatology and Venereology (EADV) Symposium, being held May 7–9, 2026, in Athens, Greece. As previously reported, the TRuE-AD4 study met both of its co-primary endpoints at Week 8, with a statistically significantly higher proportion of patients on Opzelura versus vehicle cream achieving EASI75 (≥75% improvement in Eczema Area and Severity Index score from baseline) and, separately, IGA-TS (Investigator's Global Assessment Treatment Success, defined as an IGA score of 0 [clear] or 1 [almost clear] with at least a two-point improvement from baseline).1 Patients who
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 15:03:00 EEST | Press release
Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L. Saver, MD, UCLA, and Principal Investigator of DISTALS. “What’s important is that both the device and the trial were designed specifically for distal stroke. By using a device built for these small vessels and mea
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 15:00:00 EEST | Press release
Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have faced two critical dining pain points: [Pain Point 1] The Information Gap: Most available resources are tailored for tourists, making it difficult to find the true loc
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 15:00:00 EEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom